Synedgen Announces Appointment of Dr. Laura Saward as Chief Scientific Officer

– Accomplished leader with significant expertise in therapeutic drug development and
licensure as well as a successful track record of collaboration with government agencies

CLAREMONT, Calif., February 10, 2025 – Synedgen, Inc., a biotechnology company targeting
human glycobiology to treat gastrointestinal diseases, today announced the appointment of Dr.
Laura Saward, PhD, as the company’s Chief Scientific Officer.

Dr. Saward is an accomplished biotechnology executive with more than 25 years of experience
in therapeutic drug development from preclinical to licensure. She will lead Synedgen’s scientific
strategy to further the company’s development pipeline and government partnerships.

“We are thrilled to announce the addition of Dr. Saward to our executive team as Chief Scientific
Officer. With her extensive background in drug development, and her history of managing
government contracts, she brings invaluable expertise to our organization shortly after the
signing of our up to $119 million partnership with the Biomedical Advanced Research and
Development Authority,” said Dr. Kenton Gregory, Chairman of the Board of Directors for
Synedgen. “We look forward to leveraging her experience in the years ahead as we work to
further our lead asset, MIIST305 in the dual indications of gastrointestinal acute radiation
syndrome and ulcerative colitis.”

“I am excited to join the great team at Synedgen and leverage my scientific and industry
experience to help advance their promising drug candidate MIIST305 to reach its full potential
and value, and contribute to the company’s growth strategy,” said Dr. Saward, Chief Scientific
Officer, Synedgen. “Synedgen possesses a unique technology with both biodefense and
commercial applications, underlined by the recently signed partnerships with BARDA and US
Department of Defense.”

Prior to joining Synedgen, Dr. Saward served as Executive Vice President Health and Medical
for Adva Diagnostics Inc, a start-up where she was a key member of the executive team
focused on strategy, growth planning, and partnerships expansion to strengthen the business.
Previously she held several executive roles at Emergent BioSolutions including leading the
Therapeutics Business Unit. Before joining Emergent, Dr. Saward held various leadership roles
at Cangene including Chief Scientific Officer and Vice President of research and development.
She has had the opportunity to direct the licensure of multiple products for commercial markets
and government contracts.

Dr. Saward received her B.Sc. from the University of Guelph and Ph.D. from the Faculty of
Medicine at the University of Manitoba. She completed her Post-doctoral Fellowship at Robarts
Research Institute, University of Western Ontario. Dr. Saward maintains strong ties to academia
through her adjunct professor position at University of Manitoba, Department of Medical
Microbiology and Infectious Diseases, and serves as a member of multiple boards.

About Synedgen
Synedgen, Inc. (Claremont, CA) is a biotechnology company developing Multivalent Innate
Immune Signaling Target (MIIST) therapeutics that modulate and enhance the innate immune
system. The company’s lead development candidate is MIIST305, an oral, glycocalyx targeted
induction and maintenance therapy for ulcerative colitis (UC). With US Government support,
MIIST305 is also being developed in parallel as a medical countermeasure (MCM) for
gastrointestinal acute radiation syndrome (GI-ARS). MIIST technology has been validated with
clinical trials in partnered programs and extensively peer-reviewed through twenty-two (22)
National Institutes of Health grants and Department of Defense contracts. Synedgen has an in-
house GMP manufacturing facility. For more information, please visit www.synedgen.com.
Synedgen’s GI-ARS program is funded in whole or in part with Federal funds from the
Department of Health and Human Services; Administration for Strategic Preparedness and
Response (ASPR); Biomedical Advanced Research and Development Authority, under Contract
No. 75A50124C00047.